Stocklore

Thermo Fisher Scientific, Inc. (TMO)

Biotech & Health · US stock

What changed in recent filings

  • Institutions — 5 new · 4 added · 4 reduced13F · as of end of 2026 Q2

What changed in recent SEC filings — factual, not a buy/sell recommendation.

Institutions holding Thermo Fisher Scientific, Inc.

How many of the institutions we track reported holding this stock, quarter by quarter.

max 13
2019 Q1 · 62019 Q2 · 62019 Q3 · 62019 Q4 · 62020 Q1 · 62020 Q2 · 72020 Q3 · 72020 Q4 · 82021 Q1 · 82021 Q2 · 72021 Q3 · 82021 Q4 · 82022 Q1 · 82022 Q2 · 82022 Q3 · 72022 Q4 · 62023 Q1 · 62023 Q2 · 72023 Q3 · 92023 Q4 · 82024 Q1 · 72024 Q2 · 62024 Q3 · 42024 Q4 · 62025 Q1 · 52025 Q2 · 72025 Q3 · 52025 Q4 · 92026 Q1 · 82026 Q2 · 13
19 Q122 Q326 Q2

2019 Q1: 6 → 2026 Q2: 13 institutions

Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.

Which institutions hold Thermo Fisher Scientific, Inc.

Institutions we track that reported holding this stock in their most recent 13F.

  • Baillie Gifford & Co0.29% of portfolio · held as of 2019 Q1 or earlier
  • Dodge & Cox0.80% of portfolio · held as of 2019 Q1 or earlier
  • Temasek Holdings (Singapore)1.57% of portfolio · held as of 2019 Q1 or earlier
  • Point72 Asset Management0.15% of portfolio · since 2024 Q4
  • Glenview Capital Management5.73% of portfolio · since 2025 Q2
  • Tudor Investment Corp0.05% of portfolio · since 2025 Q4
  • Viking Global Investors2.77% of portfolio · since 2025 Q4
  • Bridgewater Associates0.03% of portfolio · since 2025 Q4
  • Duquesne Family OfficeNew this quarter0.18% of portfolio · since 2026 Q2
  • Caisse de depot (Quebec)0.15% of portfolio · held as of 2026 Q2 or earlier
  • National Pension Service (Korea)0.27% of portfolio · held as of 2026 Q2 or earlier
  • Capital World Investors0.37% of portfolio · held as of 2026 Q2 or earlier
  • PRIMECAP Management0.59% of portfolio · held as of 2026 Q2 or earlier

Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.

Company overview

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Thermo Fisher Scientific, Inc. is classified under the Biotech & Health sector. See peers below.

ETFs holding Thermo Fisher Scientific, Inc.

Per SEC N-PORT · 2026-06-30 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
3.24%
VTVVANGUARD VALUE INDEX FUND
0.70%
SPY
0.29%
VOOVANGUARD 500 INDEX FUND
0.29%
IVViShares Core S&P 500 ETF
0.29%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.26%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.25%
RSPInvesco S&P 500 Equal Weight ETF
0.19%

TMO on Stocklore

  • Revenue by segmentsegment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdingsholdings and weight changes of major institutions (45-day delay)
  • Sector-relative metricsValuation and growth compared with the Biotech & Health average
See full TMO analysis →

Peers · Biotech & Health

TMO FAQ

What is Thermo Fisher Scientific, Inc. (TMO)?

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).

What sector is Thermo Fisher Scientific, Inc. in?

Thermo Fisher Scientific, Inc. is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

Where can I analyze Thermo Fisher Scientific, Inc. (TMO) stock?

On Stocklore you can see TMO's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea